Why Was Akebia Therapeutics Stock Down on Aug 5, 2026?

Akebia Therapeutics (AKBA) fell 10.612% in the fifteen minutes after its Q2 2026 report, even though the quarter beat estimates: a loss of $0.03 per share against an estimated loss of $0.04, and revenue of $49.13 million against $48.86 million expected. Total revenue was still down from $62.5 million a year earlier, and that year-over-year decline is the more important number to understand.

Akebia is a biopharmaceutical company focused on kidney disease, marketing Vafseo (vadadustat) and Auryxia (ferric citrate). The revenue decline breaks down cleanly by product: Vafseo revenue grew to $21.3 million from $13.3 million a year earlier, while Auryxia revenue fell to $25.5 million from $47.2 million as it lost ground to generic competition. That mix shift — a newer, growing drug offsetting only part of an older drug's decline to generics — explains how revenue can beat a lowered Wall Street estimate while still falling sharply from a year ago.

The more significant news in the release may be clinical: an interim analysis of the VOICE outcomes trial, covering more than 2,100 patients through June 1, 2026, met its predefined stopping criteria, showing a statistically significant improved safety outcome for Vafseo dosed three times weekly compared with older ESA anemia drugs, driven mainly by fewer hospitalizations. Vafseo's patient base grew to more than 10,500, up 41% from the first quarter, with prescriber count up 17% to about 1,200.